valproic acid has been researched along with Alcoholism in 45 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 9.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "Although mood stabilizers such as lithium (LIT), valproate (VAL), and lamotrigine (LMT) appear to be efficacious treatments for bipolar disorder (BD) in research settings, the long-term response to these mood stabilizers in clinical practice is highly variable among individuals." | 7.96 | Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study. ( Bahk, WM; Jung, YE; Kim, MD; Kwon, YJ; Lee, J; Lee, JG; Lee, K; Nam, B; Seo, JS; Song, JH; Wang, SM; Woo, YS; Yoon, BH, 2020) |
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 5.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "Although mood stabilizers such as lithium (LIT), valproate (VAL), and lamotrigine (LMT) appear to be efficacious treatments for bipolar disorder (BD) in research settings, the long-term response to these mood stabilizers in clinical practice is highly variable among individuals." | 3.96 | Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study. ( Bahk, WM; Jung, YE; Kim, MD; Kwon, YJ; Lee, J; Lee, JG; Lee, K; Nam, B; Seo, JS; Song, JH; Wang, SM; Woo, YS; Yoon, BH, 2020) |
| "Because BD-II and alcohol dependence are neurodegenerative disorders, agents with anti-inflammatory and neurotrophic effects might provide effective therapy." | 2.87 | Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study. ( Chang, YH; Chen, KC; Chen, PS; Chen, SL; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, LJ; Wang, TY; Yang, YK, 2018) |
| " Patients treated with lithium or divalproex (ongoing or assigned at screening) were randomized to receive quetiapine (dosed up to 400 mg/d over 7 days, followed by 300 to 800 mg/d flexible dosing until study end) or placebo." | 2.75 | A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. ( Brown, ES; Calabrese, JR; Kotz, M; Pettinati, HM; Raines, S; Stedman, M, 2010) |
| "Additional marijuana abuse may impact on the clinical presentation of bipolar illness and may potentially act as mediator of treatment response in this population." | 2.71 | Patient characteristics and treatment implications of marijuana abuse among bipolar alcoholics: results from a double blind, placebo-controlled study. ( Cornelius, JR; Daley, DC; Douaihy, A; Kelly, TM; Kirisci, L; Salloum, IM, 2005) |
| "The progression in severity of withdrawal symptoms (increase in CIWA-Ar above baseline) was also significantly greater in the placebo group (p < 0." | 2.70 | Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. ( Baer, JS; Malte, CA; Reoux, JP; Saxon, AJ; Sloan, KL, 2001) |
| "The occurrence of seizures and other withdrawal symptoms (tremulousness, nausea, sweating, disorientation) were noted daily." | 2.65 | Sodium valproate in the treatment of the alcohol withdrawal syndrome. ( Johnson, RH; Lambie, DG; Vijayasenan, ME; Whiteside, EA, 1980) |
| "The significant prevalence of substance use disorders among patients with psychiatric illnesses has attracted increasing interest." | 2.39 | The relationship between substance abuse and bipolar disorder. ( Brady, KT; Sonne, SC, 1995) |
| "The most common cause of seizures is epilepsy." | 1.72 | [Prospects for the development of new prolonged forms of valproic acid derivatives for the relief of convulsive syndrome]. ( Bespalov, AY; Krasnov, KA; Melekhova, AS; Reinuk, VL; Zorina, VN, 2022) |
| "Bipolar disorder (BD) spectrum and alcohol use disorders (AUDs) commonly occur together." | 1.46 | Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder. ( Adinoff, B; Brown, ES; Naglich, A, 2017) |
| "A 69-year-old man with alcohol dependence and mild cognitive impairment (MCI) suffered from repeated tonic-clonic seizures." | 1.39 | Repeated seizures in an elderly patient with alcohol dependence and mild cognitive impairment. ( Araki, Y; Hatano, K; Ishii, N; Terao, T, 2013) |
| "Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression." | 1.38 | Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. ( Brutsche, N; Cassarly, C; Franco-Chaves, J; Ibrahim, L; Luckenbaugh, DA; Marquardt, CA; Mathews, D; Zarate, CA, 2012) |
| "Subacute encephalopathy with seizures in chronic alcoholism (SESA) was first described in 1981 by Niedermeyer who reported alcoholic patients presenting with confusion, seizures and focal neurological deficits and is quite distinct from patients presenting with typical alcohol withdrawal seizures." | 1.37 | Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus. ( LaRoche, SM; Shivdat-Nanhoe, R, 2011) |
| " In this pilot study 13 adult male alcoholics received one month of oral, low dose sodium valproate (15 mg/kg/d) followed by one month of placebo followed by one month of sodium valproate at the standard anticonvulsant dosage (45 mg/kg/d)." | 1.29 | The use of sodium valproate in the treatment of alcoholism. ( Borrett, G; Duerksen, DR; German, GB; Hoeschen, L; Minuk, GY; Rockman, GE, 1995) |
| "Most patients with mild withdrawal symptoms do not require hospitalization and respond to non-pharmacologic supportive care." | 1.27 | Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. ( Naranjo, CA; Sellers, EM, 1986) |
| "Bromide was effective at subsedative doses." | 1.26 | Sodium bromide and sodium valproate: effective suppressants of ethanol withdrawal reactions in mice. ( Goldstein, DB, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (15.56) | 18.7374 |
| 1990's | 7 (15.56) | 18.2507 |
| 2000's | 17 (37.78) | 29.6817 |
| 2010's | 10 (22.22) | 24.3611 |
| 2020's | 4 (8.89) | 2.80 |
| Authors | Studies |
|---|---|
| Beresford, T | 1 |
| Ronan, PJ | 1 |
| Hipp, D | 1 |
| Schmidt, B | 1 |
| Thumm, EB | 1 |
| Temple, B | 1 |
| Wortzel, H | 1 |
| Weitzenkamp, D | 1 |
| Emrick, C | 1 |
| Kelly, J | 1 |
| Arciniegas, DB | 1 |
| Coralic, Z | 1 |
| Kapur, J | 1 |
| Olson, KR | 1 |
| Chamberlain, JM | 1 |
| Overbeek, D | 1 |
| Silbergleit, R | 1 |
| Zorina, VN | 1 |
| Bespalov, AY | 1 |
| Krasnov, KA | 1 |
| Melekhova, AS | 1 |
| Reinuk, VL | 1 |
| Woo, YS | 1 |
| Yoon, BH | 1 |
| Song, JH | 1 |
| Seo, JS | 1 |
| Nam, B | 1 |
| Lee, K | 1 |
| Lee, J | 1 |
| Jung, YE | 1 |
| Kim, MD | 1 |
| Lee, JG | 1 |
| Wang, SM | 1 |
| Kwon, YJ | 1 |
| Bahk, WM | 1 |
| Naglich, A | 1 |
| Adinoff, B | 1 |
| Brown, ES | 2 |
| Lee, SY | 1 |
| Wang, TY | 1 |
| Chen, SL | 1 |
| Chang, YH | 1 |
| Chen, PS | 1 |
| Huang, SY | 1 |
| Tzeng, NS | 1 |
| Wang, LJ | 1 |
| Lee, IH | 1 |
| Chen, KC | 1 |
| Yang, YK | 1 |
| Hong, JS | 1 |
| Lu, RB | 1 |
| Izadi Firouzabadi, L | 1 |
| Geer, K | 1 |
| Mead, P | 1 |
| Jorge, RE | 1 |
| Li, R | 1 |
| Liu, X | 1 |
| McGavin, JK | 1 |
| Shorter, DI | 1 |
| Acion, L | 1 |
| Arndt, S | 1 |
| Ishii, N | 1 |
| Terao, T | 1 |
| Araki, Y | 1 |
| Hatano, K | 1 |
| Anton, RF | 2 |
| Schacht, JP | 1 |
| Book, SW | 2 |
| Chen, H | 1 |
| Sun, J | 1 |
| Jiang, H | 1 |
| Wang, X | 1 |
| Wu, L | 1 |
| Wu, W | 1 |
| Wang, Q | 1 |
| Aukst-Margetić, B | 1 |
| Margetić, B | 1 |
| Kemp, DE | 1 |
| Gao, K | 1 |
| Ganocy, SJ | 1 |
| Elhaj, O | 1 |
| Bilali, SR | 1 |
| Conroy, C | 1 |
| Findling, RL | 1 |
| Calabrese, JR | 2 |
| Stedman, M | 1 |
| Pettinati, HM | 1 |
| Kotz, M | 1 |
| Raines, S | 1 |
| LaRoche, SM | 1 |
| Shivdat-Nanhoe, R | 1 |
| Luckenbaugh, DA | 1 |
| Ibrahim, L | 1 |
| Brutsche, N | 1 |
| Franco-Chaves, J | 1 |
| Mathews, D | 1 |
| Marquardt, CA | 1 |
| Cassarly, C | 1 |
| Zarate, CA | 1 |
| Brady, KT | 7 |
| Myrick, H | 5 |
| Henderson, S | 2 |
| Coffey, SF | 1 |
| Le Fauve, CE | 1 |
| Litten, RZ | 1 |
| Randall, CL | 1 |
| Moak, DH | 1 |
| Salloum, IM | 3 |
| Green, AI | 1 |
| Cornelius, JR | 2 |
| Daley, DC | 2 |
| Kirisci, L | 2 |
| Himmelhoch, JM | 1 |
| Thase, ME | 1 |
| Beresford, TP | 1 |
| Arciniegas, D | 1 |
| Clapp, L | 1 |
| Martin, B | 1 |
| Alfers, J | 1 |
| Bourgeois, JA | 1 |
| Koike, AK | 1 |
| Simmons, JE | 1 |
| Telles, S | 1 |
| Eggleston, C | 1 |
| Douaihy, A | 1 |
| Kelly, TM | 1 |
| Boeckh, E | 1 |
| Lambie, DG | 1 |
| Johnson, RH | 1 |
| Vijayasenan, ME | 1 |
| Whiteside, EA | 1 |
| Wilbur, R | 1 |
| Kulik, FA | 1 |
| Le Bourhis, B | 1 |
| Aufrere, G | 1 |
| Sonne, SC | 2 |
| Sonne, S | 1 |
| Lydiard, RB | 1 |
| Minuk, GY | 1 |
| Rockman, GE | 1 |
| German, GB | 1 |
| Duerksen, DR | 1 |
| Borrett, G | 1 |
| Hoeschen, L | 1 |
| Hammer, BA | 1 |
| Rosenthal, RN | 1 |
| Perkel, C | 1 |
| Singh, P | 1 |
| Anand, O | 1 |
| Miner, CR | 1 |
| Vescovi, PP | 2 |
| Volpi, R | 1 |
| Coiro, V | 2 |
| Hertzman, M | 1 |
| Longo, LP | 2 |
| Malcolm, R | 1 |
| Reoux, JP | 1 |
| Saxon, AJ | 1 |
| Malte, CA | 1 |
| Baer, JS | 1 |
| Sloan, KL | 1 |
| Campbell, T | 1 |
| Hubatch, S | 1 |
| Goldstein, DB | 1 |
| Noble, EP | 1 |
| Gillies, R | 1 |
| Vigran, R | 1 |
| Mandel, P | 1 |
| Naranjo, CA | 1 |
| Sellers, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence[NCT00194129] | Phase 3 | 31 participants (Actual) | Interventional | 1997-11-30 | Completed | ||
| Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms[NCT00202514] | Phase 2/Phase 3 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder[NCT00203528] | Phase 4 | 30 participants | Interventional | 2004-01-31 | Completed | ||
| Efficacy of Valproate Maintenance in Bipolar Alcoholics[NCT00000439] | Phase 2 | 72 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| A Randomised Trial on the Usefulness of Supportive Text Messages in the Treatment of Depressed Patients With Co-morbid Alcohol Dependency Syndrome[NCT01037868] | 56 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| Prospective Assessment of Valproate on Ethanol Withdrawal[NCT03235531] | Phase 4 | 210 participants (Anticipated) | Interventional | 2017-07-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
Number of subjects who no longer met criteria for active abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 11 |
Number of subjects who no longer met criteria for active cannabis abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 8 |
Number of subjects who no longer met criteria for active cocaine abuse or had entered into early full remission after receiving up to 6 months of open-label treatment with lithium and divalproex (NCT00194129)
Timeframe: Baseline to Month 6
| Intervention | Participants (Count of Participants) |
|---|---|
| Completers | 7 |
A relapse is a return to either a depressive, manic, hypomanic or mixed episode after a period of not have any symptoms. (NCT00194129)
Timeframe: Up to 6 months
| Intervention | weeks (Median) |
|---|---|
| Lithium Plus Divalproex | 17.8 |
| Lithium Plus Placebo | 15.9 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
6 reviews available for valproic acid and Alcoholism
| Article | Year |
|---|---|
Pharmacologic treatment of alcoholism.
Topics: Acamprosate; Alcoholism; Animals; Brain; Humans; Naltrexone; Nerve Net; Neuroimaging; Pharmacogeneti | 2014 |
The use of divalproex in the treatment of addictive disorders.
Topics: Alcoholism; Antimanic Agents; Humans; Secondary Prevention; Substance Withdrawal Syndrome; Substance | 2003 |
Novel anticonvulsants in the treatment of alcoholism.
Topics: Alcohol Deterrents; Alcoholism; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2005 |
Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants.
Topics: Alcoholism; Anticonvulsants; Carbamazepine; Humans; Hypnotics and Sedatives; Phenytoin; Primidone; S | 1981 |
The relationship between substance abuse and bipolar disorder.
Topics: Alcoholism; Bipolar Disorder; Carbamazepine; Comorbidity; Diagnosis, Dual (Psychiatry); Hospitalizat | 1995 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carb | 2001 |
14 trials available for valproic acid and Alcoholism
| Article | Year |
|---|---|
A Double-Blind Placebo-Controlled, Randomized Trial of Divalproex Sodium for Posttraumatic Irritability Greater Than 1 Year After Mild to Moderate Traumatic Brain Injury.
Topics: Alcoholism; Brain Injuries, Traumatic; Double-Blind Method; Humans; Irritable Mood; Treatment Outcom | 2022 |
Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial.
Topics: Adult; Alcoholism; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Child; Cocaine; Female; Hum | 2022 |
Add-On Memantine Treatment for Bipolar II Disorder Comorbid with Alcohol Dependence: A 12-Week Follow-Up Study.
Topics: Alcohol Drinking; Alcoholism; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; | 2018 |
Treating Alcohol Use Disorder in U.S. Veterans: The Role of Traumatic Brain Injury.
Topics: Adult; Alcohol Deterrents; Alcoholism; Brain Injuries, Traumatic; Comorbidity; Double-Blind Method; | 2019 |
A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence.
Topics: Adolescent; Adult; Affect; Aged; Alcoholism; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Co | 2009 |
A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Diagn | 2010 |
The use of divalproex in alcohol relapse prevention: a pilot study.
Topics: Adolescent; Adult; Aged; Alcoholism; Analysis of Variance; Anger; Anticonvulsants; Double-Blind Meth | 2002 |
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidit | 2005 |
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidit | 2005 |
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidit | 2005 |
Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidit | 2005 |
Patient characteristics and treatment implications of marijuana abuse among bipolar alcoholics: results from a double blind, placebo-controlled study.
Topics: Adolescent; Adult; Affect; Aged; Alcohol Drinking; Alcoholism; Antimanic Agents; Bipolar Disorder; D | 2005 |
Sodium valproate in the treatment of the alcohol withdrawal syndrome.
Topics: Adult; Alcoholism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Seizures; Substance | 1980 |
A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal.
Topics: Adult; Affect; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Dose-Response Relationship, | 1998 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Depression; Double-Blind Method; Etha | 2001 |
Utility of a new assay for carbohydrate-deficient transferrin (Biorad %CDT TIA) to monitor abstinence during a treatment outcome study.
Topics: Adult; Aged; Alcoholism; Biomarkers; Double-Blind Method; gamma-Glutamyltransferase; Humans; Middle | 2001 |
Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Ambulatory Care; Anti-Anxiety Agents; Anticonvulsant | 2002 |
25 other studies available for valproic acid and Alcoholism
| Article | Year |
|---|---|
[Prospects for the development of new prolonged forms of valproic acid derivatives for the relief of convulsive syndrome].
Topics: Alcoholism; Anticonvulsants; Epilepsy; Humans; Seizures; Substance Withdrawal Syndrome; Valproic Aci | 2022 |
Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study.
Topics: Adult; Alcoholism; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Female; Fo | 2020 |
Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder.
Topics: Alcoholism; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Humans; Quetiapin | 2017 |
Severe hyperammonaemic encephalopathy resulting from the overlap between hepatic and valproate encephalopathy.
Topics: Alcoholism; Brain Diseases; Epilepsy; Humans; Hyperammonemia; Hypertension, Portal; Male; Middle Age | 2018 |
Repeated seizures in an elderly patient with alcohol dependence and mild cognitive impairment.
Topics: Aged; Alcohol Withdrawal Seizures; Alcoholism; Cognitive Dysfunction; Diazepam; Humans; Male; Valpro | 2013 |
Inferring Alcoholism SNPs and Regulatory Chemical Compounds Based on Ensemble Bayesian Network.
Topics: Alcoholism; Bayes Theorem; Chloroprene; Databases, Genetic; Gene Expression Regulation; Humans; Poly | 2017 |
Stuttering as a side-effect of divalproex sodium.
Topics: Alcoholism; Antimanic Agents; Humans; Male; Middle Aged; Stress Disorders, Post-Traumatic; Stutterin | 2008 |
Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus.
Topics: Acetamides; Alcohol Withdrawal Seizures; Alcoholism; Anticonvulsants; Brain Diseases; Confusion; Dif | 2011 |
Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
Topics: Adult; Alcoholism; Antidepressive Agents; Bipolar Disorder; Cross-Over Studies; Double-Blind Method; | 2012 |
Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity.
Topics: Alcoholism; Animals; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Humans; Mental | 2004 |
Reduction of affective lability and alcohol use following traumatic brain injury: a clinical pilot study of anti-convulsant medications.
Topics: Adult; Alcoholism; Anticonvulsants; Anxiety Disorders; Brain Injuries; Carbamazepine; Female; Humans | 2005 |
Adjunctive valproic acid for delirium and/or agitation on a consultation-liaison service: a report of six cases.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Delirium; Fever; Humans; Injections, Intra | 2005 |
[The alcohol withdrawal syndrome and its therapy].
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Humans; Middle Aged; Patient Compliance; Psychomotor | 1980 |
Effects of sodium dipropylacetate on the ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Behavior, Animal; Humans; Male; Rats; Rats, Inbred Strains; Substance Withdrawa | 1980 |
Valproate treatment of comorbid panic disorder and affective disorders in two alcoholic patients.
Topics: Adult; Alcoholism; Bipolar Disorder; Comorbidity; Depressive Disorder; Dose-Response Relationship, D | 1994 |
The use of sodium valproate in the treatment of alcoholism.
Topics: Administration, Oral; Adult; Aged; Alcoholism; Anticonvulsants; Anxiety; Follow-Up Studies; Humans; | 1995 |
Valproate treatment of alcohol withdrawal and mania.
Topics: Adult; Alcoholism; Bipolar Disorder; Ethanol; Humans; Male; Psychotic Disorders; Substance Withdrawa | 1996 |
Alcoholism abolishes the gamma-aminobutyric acid (GABA)ergic control of GH secretion in humans.
Topics: Adult; Alcoholism; Baclofen; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Human Growth Hormo | 1998 |
Valproate for alcoholics with bipolar disorder.
Topics: Adult; Alcoholism; Anticonvulsants; Bipolar Disorder; Comorbidity; Female; gamma-Glutamyltransferase | 1999 |
Divalproex sodium to treat concomitant substance abuse and mood disorders.
Topics: Adolescent; Adult; Alcoholism; Bipolar Disorder; Comorbidity; Female; Humans; Male; Middle Aged; Moo | 2000 |
Different control of GH secretion by gamma-amino- and gamma-hydroxy-butyric acid in 4-year abstinent alcoholics.
Topics: Adult; Alcoholism; Baclofen; Biomarkers; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Growth | 2001 |
Divalproex sodium for alcohol withdrawal and relapse prevention: a case report.
Topics: Alcoholism; Anticonvulsants; Ethanol; Hospitalization; Humans; Male; Middle Aged; Secondary Preventi | 2000 |
Sodium bromide and sodium valproate: effective suppressants of ethanol withdrawal reactions in mice.
Topics: Alcoholism; Animals; Bromides; Dose-Response Relationship, Drug; Humans; Male; Mice; Postural Balanc | 1979 |
The modification of the ethanol withdrawal syndrome in rats by di-n-propylacetate.
Topics: Acoustic Stimulation; Alcoholism; Animals; gamma-Aminobutyric Acid; Humans; Male; Motor Activity; Ra | 1976 |
Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome.
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Benzodiazepines; Chl | 1986 |